Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

$OPNT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $OPNT alert in real time by email

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with over 20 years of commercial and executive experience, to Chairman of its Board of Directors, effective January 1, 2021. Mr. Collard joined the Opiant board in 2018. Gabrielle Silver, M.D., who has served as Lead Independent Director since October, 2018, will remain an independent director on the Board and continue to be Chairman of the Nominating and Governance Committee.

“As we pursue our mission to deliver new medicines for addiction and overdose, I couldn’t be more excited to have Craig as Chairman to our Board of Directors,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant.“As CEO of three pharmaceutical companies, and founder of two, Craig has terrific experience in creating shareholder value through successfully bringing new medicines to market. His appointment as Chairman is particularly timely as we continue to advance OPNT003, nasal nalmefene, a potential best-in-class treatment for opioid overdose. I also want to thank Gaby for her leadership during an important time in Opiant’s journey and am delighted that she will continue to serve as a valued independent member of our Board.”

“Opiant offers a unique profile as a company focused on addiction and overdose,” said Craig Collard, incoming Chairman, Board of Directors, Opiant. “I look forward to working closely with Roger and the rest of the Board as we enter a new phase and move toward potential commercialization of our lead pipeline asset in the next few years.”

Mr. Collard is currently the CEO of Veloxis Pharmaceutics, Inc., a transplant-focused pharmaceutical company, now a subsidiary of Asahi Kasei after its acquisition of Veloxis for $1.3 billion in 2020. Prior to this, he served as the CEO and Chairman of Cornerstone Therapeutics, Inc., a pharmaceutical company he founded in 2004, until February 2014 when the company was purchased for $300 million by Chiesi Pharmaceuticals, Inc. Before founding Cornerstone, Mr. Collard served as President and CEO of Carolina Pharmaceuticals, Inc., a pharmaceutical company he founded in May 2003. From 1992 to 2003, Mr. Collard served in various commercial roles at Verum Pharmaceuticals, Inc., and DJ Pharma, Inc. Mr. Collard is a member of the Board of Directors of Veloxis, Sierra Oncology, Inc. and TerrAscend Corporation. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia.

About Opiant Pharmaceuticals, Inc. 
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled “Risk Factors.”  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com


Get the next $OPNT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OPNT

DatePrice TargetRatingAnalyst
12/9/2021$42.00Outperform
Oppenheimer
More analyst ratings

$OPNT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Deepwatch Names Mel Wesley as Chief Financial Officer

    Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press

    $OPNT
    $SCOR
    $FEYE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Business Services
    Consumer Discretionary
  • Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

    CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023Indivior and Opiant continue to anticipate completing the proposed merger in the first quarter of 2023 SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE: INDV). Following the expiration of the waiti

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

    SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be acquired by Indivior PLC (LSE: INDV). The waiting period expired on February 2, 2023, without any action taken by the Federal Trade Commission (FTC). The HSR Act is a key U.S. antitrust statute that enables the FTC and Department of Justice (DOJ) to review proposed merger transactions by requiring the parties to observe a waiting period before closing their transaction. Completion of the tr

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OPNT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OPNT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OPNT
SEC Filings

See more

$OPNT
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for OPVEE issued to OPIANT PHARMACEUTICALS INC

    Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (ORIG-1) with active ingredient NALMEFENE has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • May 22, 2023 - FDA Approves Prescription Nasal Spray to Reverse Opioid Overdose

    For Immediate Release: May 22, 2023 Today, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older. This is the first FDA approval of nalmefene hydrochloride nasal spray for health care and community use. “The agency continues to advance the FDA

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for OPVEE (nalmefene) issued to OPIANT PHARMACEUTICALS INC

    Submission status for OPIANT PHARMACEUTICALS INC's drug OPVEE (nalmefene) (ORIG-1) with active ingredient OPVEE (nalmefene) has changed to 'Approval' on 05/22/2023. Application Category: NDA, Application Number: 217470, Application Classification: Type 3 - New Dosage Form

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OPNT
Leadership Updates

Live Leadership Updates

See more
  • Deepwatch Names Mel Wesley as Chief Financial Officer

    Successful finance and cybersecurity industry veteran to support rapid growth Deepwatch, the leader in advanced managed detection and response (MDR) security, announced today the appointment of Mel Wesley as Chief Financial Officer (CFO). Wesley is a seasoned finance executive with over 25 years of experience in financial planning, analysis, and operational finance, with a proven track record of driving growth and building high-performance finance teams. For the past 18 years, he has served as CFO for publicly traded and private technology companies. As Deepwatch's CFO, Wesley will support the Company during hyper-growth while overseeing finance, legal and corporate development. This press

    $OPNT
    $SCOR
    $FEYE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Business Services
    Consumer Discretionary
  • MindMed Strengthens Board with Appointment of Two New Independent Directors

    NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com

    $MNMD
    $OPNT
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

    SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

    $BYSI
    $CPRX
    $OPNT
    $PALI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$OPNT
Financials

Live finance-specific insights

See more
  • Indivior PLC to Acquire Opiant Pharmaceuticals

    Indivior to acquire Opiant Pharmaceuticals for total consideration of $28.00 per share comprising of an upfront cash payment of $20.00 per share at closing plus contingent value rights (CVRs) worth up to $8.00 per share in cash, payable on achievement of certain net revenue thresholds for OPNT003Upfront payment represents a 111% premium to Opiant's closing share price of November 11, 2022, and 99% premium to Opiant's 30-day volume-weighted average share price; total consideration, inclusive of potential CVR payments, represents a premium of up to 195% and 178%, respectivelyAcquisition will expand Indivior's portfolio of addiction therapies and leverage its expertise and resources to maximize

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Indivior To Acquire Opiant Pharmaceuticals

    Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to Confront Illicit Synthetic Opioids Like Fentanyl Potential Annual OPNT003 Net Revenue of $150 Million to $250 Million Acquisition Expected to be Accretive to Earnings after the Second Full Year of Launch of OPNT003 Indivior to Host Investor Call at 8:00 am U.S. Eastern Today RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) ("Opiant") today announced that the companies have entered

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

    SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant" or "Company") (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.   The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit h

    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$OPNT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more